What it is
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist studied for obesity and metabolic liver disease.
Evidence boundary
Human trial evidence exists, but it is still investigational.
Trial evidence
- PMID 40922121 — Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
- PMID 40489581 — Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
- PMID 41466530 — Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
- PMID 41787737 — Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Preparation and measurement
Reconstitution: 10 mg vial + 1.5 mL BAC = 6.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 | 600 mcg | 9 U (0.09 mL) | Once weekly | 600 mcg/week |
| Weeks 3–4 | 1.2 mg | 18 U (0.18 mL) | Once weekly | 1.2 mg/week |
| Weeks 5–6 | 1.8 mg | 27 U (0.27 mL) | Once weekly | 1.8 mg/week |
| Weeks 7–8 | 2.4 mg | 36 U (0.36 mL) | Once weekly | 2.4 mg/week |
| Weeks 9–10 | 3.6 mg | 54 U (0.54 mL) | Once weekly | 3.6 mg/week |
| Weeks 11–12 | 4.8 mg | 72 U (0.72 mL) | Once weekly | 4.8 mg/week |
| Week 13+ | 6 mg | 90 U (0.9 mL) | Once weekly | 6 mg/week |
Weeks 1–2
- Dose
- 600 mcg
- Draw / measure
- 9 U (0.09 mL)
- Frequency
- Once weekly
- Weekly total
- 600 mcg/week
Weeks 3–4
- Dose
- 1.2 mg
- Draw / measure
- 18 U (0.18 mL)
- Frequency
- Once weekly
- Weekly total
- 1.2 mg/week
Weeks 5–6
- Dose
- 1.8 mg
- Draw / measure
- 27 U (0.27 mL)
- Frequency
- Once weekly
- Weekly total
- 1.8 mg/week
Weeks 7–8
- Dose
- 2.4 mg
- Draw / measure
- 36 U (0.36 mL)
- Frequency
- Once weekly
- Weekly total
- 2.4 mg/week
Weeks 9–10
- Dose
- 3.6 mg
- Draw / measure
- 54 U (0.54 mL)
- Frequency
- Once weekly
- Weekly total
- 3.6 mg/week
Weeks 11–12
- Dose
- 4.8 mg
- Draw / measure
- 72 U (0.72 mL)
- Frequency
- Once weekly
- Weekly total
- 4.8 mg/week
Week 13+
- Dose
- 6 mg
- Draw / measure
- 90 U (0.9 mL)
- Frequency
- Once weekly
- Weekly total
- 6 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
600 mcg weekly is the cautious start.
-
1.2 mg, 1.8 mg, and 2.4 mg are the early steps.
-
3.6 mg, 4.8 mg, and 6 mg are the higher collected steps.
-
Keep the schedule aligned to study-style weekly escalation, not a finished label.
-
Weight-loss response
-
Liver enzyme / MASLD or MASH response
-
GI effects during escalation
-
Tolerability
-
Do not read this as an approved product.
Practical rules
- Subcutaneous, once weekly.
- Rotate injection sites.
- Use this as an investigational reference, not a product label.
- Keep protein and resistance training in the plan if lean mass matters.
Research coverage
Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on Survodutide.
- GLP-1 Agonists for MASH Fibrosis: an Overview Sep 8, 2026
A Cell Reports Medicine review surveys incretin-based therapies for MASH fibrosis — from FDA-approved semaglutide to emerging dual and triple GLP-1 agonists.
- Survodutide for Obesity: Phase 3 SYNCHRONIZE-1 Results Aug 31, 2026
The NEJM-published SYNCHRONIZE-1 trial shows survodutide 6.0 mg achieved -13.0% mean weight loss over 76 weeks in adults with obesity without diabetes.